The use of lentinan for treating gastric cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 5, 2013, Pages 681-688

  Ina, Kenji ^a   Kataoka, Takae ^a   Ando, Takafumi ^b  

^a Nagoya Memorial Hospital   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

glucan; Gastric cancer; Lentinan

Indexed keywords

CISPLATIN; COMPLEMENT RECEPTOR; DOCETAXEL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; LENTINAN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

BREAST CANCER; CYTOTOXICITY; HUMAN; IMMUNE SYSTEM; NONHUMAN; REVIEW; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LENTINAN; PLANT EXTRACTS; SHIITAKE MUSHROOMS; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84880171040     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313050002     Document Type: Review

References (100)

1. Hohenberger, P.; Gretshel, S. Gastric cancer. Lancet, 2003, 362, 305-315.
2. Kamangar, F.; Dorce, G.M.; Anderson, W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 2006, 24, 2137-2150.
3. Bernardi, R.; Scartozzi, M.; Romagnoli, E.; Antognoli, S.; Cascinu, S. Gastric cancer treatment: A system review. Oncol. Rep., 2004, 11, 911-916.
4. Wohler, S.S.; Raderer, M.; Hejna, M. Palliative chemotherapy for advanced gastric cancer. Annals Oncol., 2004, 15, 1585-1595.
5. Sastre, J.; Garcia-Saenz, J.A.; Diaz-Rubio, E. Chemotherapy for gastric cancer. World J. Gastroenterol., 2006, 12, 204-213.
6. Chen, J.; Seviour, R. Medicinal importance of fungal α-(1, 3), (1, 6)-glucans. Mycol. Res., 2007, 635-652.
7. Chen, J.; Raymond, K. β-glucans in the treatment of diabetes and associated cardiovascular risks. Vascul. Health Risk Manag., 2008, 4, 1265-1272.
8. Vetvicka, V. Glucan-immunostimulant, adjuvant, potential drug. World J. Clin. Oncol., 2011, 2, 115-119.
9. Murphy, E.A.; Davis, J.M.; Carmichael, M.D. Immune modulating effects of ee-glucan. Curr. Opi. Clin. Nutr. Metab. Care, 2010, 13, 656-661.
10. Tanaka, K.; Tanaka, Y.; Suzuki, T.; Mizushima, T. Protective effect of ee-(1,3β1,6)-D-glucan against irritant-induced gastric lesions. Br. J. Nutr., 2011, 106, 475-485.
11. Sakamoto, J.; Teramukai, S.; Nakazato, H.; Sato, Y.; Uchino, J.; Taguchi, T. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: A metaanalysis of centrally randamized controlled clinical trials. J. Immunother., 2002, 25, 405-412.
12. Hamuro, J.; Rollinghoff, M.; Wagner, H. α-(1, 3) glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res., 1978, 38, 3080-3085.
13. Chan, G.C.; Chan, W.K.; Sze, D.M. The effects of β-glucan on human immune and cancer cells. J. Hematol. Oncol., 2009, 2, 25-29.
14. Nakazato, H.; Koike, A.; Saji, S.; Ogawa, N.; Sakamoto, J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet, 1994, 343, 1122-1126.
15. Toge, T.; Yamaguchi, Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol. Rep., 2000, 7, 1157-1161.
16. Oba, K.; Teramaki, S.; Kobayashi, M.; Matsui, T.; Kodera, Y.; Sakamoto, J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resection of gastric cancer. Cancer Immunol. Immunother., 2007, 56, 905-911.
17. Chihara, G.; Maeda, Y.; Hamuro, J.; Sasaki, T.; Fukuoka, F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature, 1969, 222, 687-688.
18. Chihara, G.; Hamuro, J.; Maeda, Y.; Arai, Y.; Fukuoka, F. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes. Cancer Res., 1970, 30, 2776-2781.
19. Oba, K.; Kobayashi, M.; Matsui, T.; Kodera, Y.; Sakamoto, J. Individual patient based meta-analysis of lentinan for unresectable/ recurrent gastric cancer. Anticancer Res., 2009, 29, 2739-2746.
20. Nakano, H.; Namatame, K.; Nemoto, H.; Motohashi, H.; Nishiyama, K.; Kumada, K. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life. Hepato-Gastroenterol., 1999, 46, 2662-2668.
21. Brown, G.D.; Gordon, S. Fungal β-glucans and mammalian immunity. Immunity, 2003, 19, 311-315.
22. Almand, B.; Resser, J.R.; Lindman, B.; Nadaf, S.; Clark, J.I.; Kwon, E.D.; Carbone, D.P.; Gabrilovich, D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res., 2000, 6, 1755-1766.
23. Ratta, M.; Fagnoni, F.; Curti, A.; Vescovini, R.; Sansoni, P.; Oliviero, B.; Fogl, M.; Ferri, E.; Della Cuna, G.R.; Tura, S.; Baccarani, M.; Lemoli, R.M. Dendritic cells are functionally defective in multiple myeloma. Blood, 2002, 100, 230-237.
24. Mushiake, H.; Tsunoda, T.; Nukatsuka, M.; Shimao, K.; Fukushima, M.; Tahara, H. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol. Immunother., 2005, 54, 120-126.
25. van de Winkel, J.G.; Capel, P.J. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today, 1993, 14, 215-221.
26. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer, 2001, 1, 118-129.
27. Tani, M.; Tanimura, H.; Yamaue, H.; Iwahashi, M.; Tsunoda, T.; Tamai, M.; Noguchi, K.; Arii, K. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. Eur. J. Clin. Pharmacol., 1992, 42, 623-627.
28. Czop, J.K.; Austen, K.F. A β-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particular activators of alternative complement pathway. J. Immunol., 1985, 134, 2588-2593.
29. Okuda, T.; Yoshioka, Y.; Ikekawa, T.; Chihara, G.; Nishioka, K. Anti-complementary activity of antitumor polysaccharides. Nature, 1972, 238, 59-60.
30. Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravtech, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med, 2000, 6, 443-446.
31. Modak, S.; Koehne, G.; Vickers, A.; O'Reilly, R.J.; Cheung, N. Rituximab therapy of lymphoma is enhanced by orally administered (1-3), (1-4)-D-(-glucan. Leukemia. Res., 2005, 29, 679-683.
32. Brown, G.D.; Taylor, P.R.; Reid, D.M.; Willment, J.A.; Williams, D.L.; Pomares, L.M.; Wong, S.Y.C.; Gordon, S. Dectin-1 is a major mm-glucan receptor on macrophages. J. Exp. Med., 2002, 196, 407-412.
33. Brown, G.D. Dectin-1: A signaling non-TLR pattern-recognition receptor. Nat. Rev. Immunol., 2006, 6, 33-43.
34. Goodridge, H.S.; Wolf, A.J.; Underhill, D.M. β-glucan recognition by the innate immune system. Immunol. Rev., 2009, 230, 38-50.
35. Kataoka, K.; Muta, T.; Yamazaki, S.; Takeshige, K. Activation of macrophages by linear (1, 3)-mm-D-glucans. J. Biol. Chem., 2002, 277, 36825-36831.
36. Underhill, D.M.; Rossnagle, E.; Lowell, C.A.; Simmons, R.M. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood, 2005, 106, 2543-2550.
37. Rogers, N.C.; Slack, E.C.; Edwards, A.D.; Nolte, M.A.; Schulz, O.; Schweighoffer, E.; Williams, D.L.; Gordon, S.; Tybulewicz, V.L.; Brown, G.D.; Reis e Sousa, C. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity, 2005, 22, 507-517.
38. Young, S.H.; Fraser, D.G.; Shi, X.; Castranova, V. Molecular mechanism of tumor necrosis factor-mmmproduction in 1, 3-pp-glucanactivated macrophages. J. Biol. Chem., 2001, 276, 20781-20787.
39. Thornton, B.P.; Vetvicka, V.; Pitman, M.; Goldman, R.C.; Ross G.D. Analysis of the sugar specificity and molecular location of the cc-glucan-binding lectin site of complment receptor type 3 (CD11b/CD18). J. Immunol., 1996, 156, 1235-1246.
40. Xia, Y.; Ross, G.D. Generation of recombinant fragments of CD11b expressing the functional CC-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol., 1999, 162, 7285-7293.
41. Li, B.; Allendorf, D.J.; Hansen, R.; Marroquin, J.; Ding, C.; Cramer, D.E.; Yan, J. Yeast CC-glucan amplifies phagocyte killing of iC3b-opsonized tumor cell via complement receptor 3-Sykphosphatidylinositol 3-kinase pathway. J. Immunol., 2006, 177, 1661-1669.
42. Cain, J.A.; Newman, S.L.; Ross, G.D. Role of complement receptor type three and secure opsonins in the neutrophil response to yeast. Complement., 1987, 4, 75-86.
43. Ross, G.D.; Cain, J.A.; Myones, B.L.; Newman, S.L.; Lachmann, P.J. Specificity of membrane complement receptor type three (CR3) for (-glucan. Complement, 1987, 4, 61-74.
44. Vetvicka, V.; Thornton, B.P.; Ross, G.D. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest., 1996, 98, 50-61.
45. Allendorf, D.J.; Yan, J.; Ross, G.D.; Hansen, R.D.; Baran, J.T.; Subbarao, K.; Wang, L.; Haribabu B. C5a-mediated leukotriene Bamplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and ii-glucan. J. Immunol., 2005, 174, 7050-7056.
46. Wang, S.C.; Zhang, L.; Hortobagyi, G.N.; Hung, M.C. Targeting HER2: Recent developments and further directions for breast cancer patients. Semin. Oncol., 2001, 28, 21-29.
47. Gelderman, K.; Tomlinson, A.S.; Ross, G.D.; Gorter, A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol., 2004, 25, 158-164.
48. Rice, P.J.; Kelley, J.L.; Kogan, G.; Ensley, H.E.; Kalbfleisch, J.H.; Browder, I.W.; Williams, D.L. Human monocytes scavenger receptors are pattern recognition receptors for (1-3)-rr-D-glucans. J. Leukoc. Biol., 2002, 72, 140-146.
49. Assanasen, C.; Mineo, C.; Seetharam, D.; Yuhanna, I.S.; Marcel, Y.L.; Connelly, M.A.; Williams, D.L.; de la Llera Moya, M.; Shaul, P.W.; Silver, D.L. Cholesterol binding, efflux, and a PDZinteracting domain of scavenger receptor-BI mediate HDL-initiated signaling. J. Clin. Invest., 2005, 115, 969-977.
50. Mineo, C.; Yuhanna, I.S.; Quon, M.J.; Shaul, P.W. High Density Lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinase. J. Biol. Chem, 2003, 278, 9142-9149.
51. Zimmerman, J.W.; Lindermuth, J.; Fish, P.A.; Palace, G.P.; Stevenson, T.T.; DeMong, D.E. A novel carbohydrateglycosphingolipid interaction between a nn-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J. Biol. Chem., 1998, 273, 22014-22020.
52. Hahn, P.Y.; Evans, S.E.; Kottom, T.J.; Standing, J.E.; Pagano, R.E.; Limper, A.H. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J. Biol. Chem., 2003, 278, 2043-2050.
53. Evans, S.E.; Hahn, P.Y.; McCann, F.; Kottom, T.J.; Pavlovic, Z.V. Pneumocystis cell wall PP-glucan stimulates alveolar epithelial cell chemokine generation through nuclear factor-ccccc-dependent mechanism. Am. J. Respir. Cell. Mol. Biol., 2005, 32, 490-497.
54. Wakshull, E.; Brunke-Reese, D.; Lindermuth, J.; Fisette, L.; Nathans, R.S.; Crowley, J.J.; Tufts, J.C.; Zimmerman, J.; Mackin, W.; Adams, D.S. PGG-glucan, a soluble WW-(1, 3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-NNNN-like factor in human PMN: Evidence for a glycosphingolipid pp-(1, 3)-glucan receptor. Immunopharmacol., 1998, 41, 89-107.
55. Haba, S.; Hamaoka, T.; Takatsu, K.; Kitagawa, M. Selective suppression of T-cell activity in tumor-bearing mice and its improvement by lentinan, a potent antitumor polysaccharide. Int. J. Cancer, 1976, 18, 93-104.
56. Langstein, H.; Norton, A. Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am., 1991, 5, 103-203.
57. Hamuro, J.; Rollinghoff, M.; Wagner, H. Induction of cytotoxic peritoneal exudates cells by T-cell immune adjuvant of the pp-1, 3-glucan-type lentinan and its analogs. Immunology, 1980, 39, 551-559.
58. Peter, G.; Karoly, V.; Imre, B.; Janos, F.; Kaneko, Y. Effects of lentinan on cytotoxic functions of human lymphocytes. Immunopharmac. Immunotoxic., 1988, 10, 157-163.
59. Matsuoka, H.; Seo, Y.; Wakasugi, H.; Saito, T.; Tomoda, H. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res., 1997, 17, 2751-2756.
60. Miyakosi, H., Aoki, T. Acting mechanisms of lentinan in human. Int. J. Immunopharmac., 1984, 6, 373-379.
61. Oka, M.; Hazama, S.; Suzuki, M.; Wang, F.; Wadamori, K.; Iizuka, N.; Takeda, S.; Akitomi, Y.; Ohba, Y.; Kajiwara, K.; Suga, T.; Suzuki, T. In vitro and in vivo analysis of human leukocyte binding by the antitumor polysaccharide, lentinan. Int. J. Immunopharmac., 1996, 18, 211-216.
62. Hamuro, J.; Hadding, U.; Bitter-Suermann, D. Solid phase activation of alternative pathway of complement by-1, 3-glucans and its possible role for tumor regressing activity. Immunology, 1978, 34, 695-705.
63. Herlyn, D.; Kaneko, Y.; Powe, J.; Aoki, T.; Koprowski, H. Monoclonal antibody-dependent murine macrophage-mediated cytotoxicity against human tumors is stimulated by lentinan. Jpn. J. Cancer Res., 1985, 76, 37-42.
64. Cheung, N.-K.V.; Modak, S.; Vickers, A.; Knuckles, B. Orally administered aa-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother., 2002, 51, 557-564.
65. Murata, Y.; Shimamura, T.; Tagami, T.; Takatsuki F.; Hamuro, J. The skewing to Th1 induced by lentinan is directed through the distinctive cytokine production by macrophages with elevated intracellular glutathione content. Int. Immunophamacol., 2002, 2, 673-689.
66. Yoshino, S.; Tabata, T.; Hazama, S.; Iizuka, N.; Yamamoto, K.; Hirayama, M.; Tangoku, A.; Oka, M. Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancer. Anticancer Res., 2000, 20, 4707-4712.
67. Tabuchi, T.; Ubukata, H.; Sato, S.; Nakata, I.; Goto, Y.; Watanabe, Y.; Hashimoto, T.; Mizuta, T.; Adachi, M.; Soma, T. Granulocytapheresis as a possible cancer treatment. Anticancer Res., 1995, 15, 985-990.
68. Petrie, H.T.; Klassen, L.W.; Kay, H.D. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J. Immunol., 1985, 134, 230-234.
69. Shau, H.Y.; Kim, A. Suppression of lymphokine-activated killer induction by neutrophils. J Immunol, 1988, 141, 4395-4402.
70. Donskov F and von der Masse H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24, 1997-2005.
71. Liu, H.; Tabuchi, T.; Takemura, A.; Kasuga, T.; Motohashi, G.; Hiraishi, K.; Katano, M.; Nakada, I.; Ubukata, H.; Tabuchi, T. The granulocyte/lymphocyte ratio as an independent predictor of tumor growth, metastasis, and progression: its clinical application. Mol. Med. Rep., 2008, 1, 699-704.
72. Shimada, H.; Takiguchi, N.; Kainuma, O.; Soda, H.; Ikeda, A.; Cho, A.; Miyazaki, A.; Gunji, H.; Yamamoto, H.; Nagata, M. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric. Cancer, 2010, 13, 170-176.
73. Ina, K.; Furuta, R.; Kataoka, T.; Kayukawa, S.; Yoshida, T.; Miwa, T.; Yamamura, Y.; Takeuchi Y. Lentinan prolonged the survival of patients with unresectable or recurrent gastric cancer receiving S-1-based chemotherapy. World J. Clin. Oncol., 2011, 2, 339-343.
74. Lenz, H.J.; Lee, F.C.; Haller, D.G.; Singh, D.; Benson, A.B.; Strumberg, D.; Yanagihara, R.; Yao, J.C.; Phan, A.T.; Ajani, J.A. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer, 2007, 109, 33-40.
75. Koizumi, W.; Narahara, H.; Hara, T.; Takagane, A.; Akiya, T.; Takagi, M.; Miyashita, K.; Nishizaki, T.; Kibayashi, O.; Takiyama, W.; Toh, Y.; Nagaie, T.; Takagi, S.; Yamamura, Y.; Yanaoka, K.; Orita, H.; Takeuchi, M. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol., 2008, 9, 215-221.
76. Shirasaka, T.; Shimamoto, Y.; Ohshino, H.; Yamaguchi, M.; Kato, T.; Yonekura, K.; Fukushima, M. Development of a novel form of an oral 5-fluorouracil derivative (S1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulations. Anticancer Drugs, 1996, 7, 548-557.
77. Scanlon, K.J.; Newmann, E.M.; Lu, Y.; Priest, D.G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA, 1986, 83, 8923-8925.
78. Iwase, H.; Shimada, M.; Tsuzuki, T.; Horiuchi, Y.; Kumada, S.; Haruta, J.; Yamaguchi, T.; Sugihara, M.; Ina, K.; Kusugami, K.; Goto, H. A phase II multicentric trial of S-1 combined with 24 hinfusion of cisplatin in patients with advanced gastric cancer. Anticancer Res., 2005, 25, 1297-1302.
79. Ohtsu, A.; Boku, N.; Tamura, F.; Muro, K.; Shimada, Y.; Saigenji, K.; Akazawa, S.; Kitajima, M.; Kanamaru, R.; Taguchi, T. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am. J. Clin. Oncol., 1998, 21, 416-419.
80. Sulkes, A.; Smyth, J.; Sessa, C.; Drinx, L.Y.; Vermorken, J.B.; Kaye, S.; Wanders, J.; Franklin, H.; LeBail, N.; Verweij, J. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTIC Early Clinical Trials Group. Br. J. Cancer, 1994, 70, 380-38.
81. Yamaguchi, K.; Shimamura, T.; Hyodo, I.; Koizumi, W.; Narahara, H.; Komatsu, Y.; Kato, T.; Saitoh, S.; Akiya, T.; Munakata, M.; Miyata, Y.; Takiuchi, H.; Nakano, S.; Esaki, T.; Kinjo, F.; Sakata, Y. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br. J. Cancer, 2006, 94, 1803-1808.
82. Sato, Y.; Takayama, T.; Sagawa, T.; Takahashi, Y.; Ohnuma, H.; Okubo, S.; Shintani, N.; Tanaka, S.; Kida, M.; Sato, Y.; Ohta, H.; Miyanishi, K.; Sato, T.; Takimoto, R.; Kobune, M.; Yamaguchi, K.; Hirata, K.; Niitsu, Y.; Kato, J. Phase II study of S-1, docetaxel, and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother. Pharmacol., 2010, 66, 721-728.
83. Ina, K.; Furuta, R.; Kataoka, T.; Kayukawa, S.; Iwase, H. Prospective study of the triple combination chemotherapy consisting of paclitaxel, S-1, and 24-hour infusion of cisplatin (PSC) against inoperable highly advanced gastric cancer. In: Manag. Gastric Cancer, Ed.; InTech. 2011; pp. 119-126.
84. Iwase, H.; Shimada, M.; Tsuzuki, T.; Ina, K.; Sugihara, M.; Haruta, J.; Shinoda, M.; Kumada, T.; Goto, H. A phase II multi-study of triple therapy with paclitaxel, S-1, and cisplatin in patients with advanced gastric cancer. Oncology, 2011, 80, 76-83.
85. Ina, K.; Kataoka, T.; Takeuchi, Y.; Fukuoka, T.; Miwa, T.; Nishio, T.; Furuta, R.; Masaki, A.; Mori, F.; Kayukawa, S.; Nagao, S.; Ando, T.; Goto, H. Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer. Oncol. Rep., 2008, 20, 259-264.
86. Ishida, T.; Joh, T.; Uike, N.; Yamamoto, K.; Utsunomiya, A.; Yoshida, S.; Saburi, Y.; Miyamoto, T.; Takemoto, S.; Suzushima, H.; Tsukasaki, K.; Nosaka, K.; Fujiwara, H.; Ishitsuka, K.; Inagaki, H.; Ogura, M.; Akinaga, S.; Tomonaga, M.; Tobinai, K.; Ueda, R. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J. Clin. Oncol., 2012, 30, 837-842.
87. Hudziak, R.M.; Lewis, G.D.; Winget, M.; Fendly, B.M.; Shepard, H.M.; Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizers human breast tumor cells to tumor necrosis factor. Mol. Cell Biol., 1989, 9, 1165-1172.
88. Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Eng. J. Med., 2007, 357, 39-51.
89. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235, 177-182.
90. Lewis, G.D.; Figari, I.; Fendly, B.; Wong, W.L.; Carter, P.; Gorman, C.; Shepard, M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother., 1993, 37, 255-263.
91. Baselga, I.; Norton, L.; Albanell, J.; Kim, Y.M.; Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 1998, 58, 2825-2831.
92. Pegram, M.D.; Lipton, A.; Hayes, D.F.; Weber, B.L.; Baselga, J.M.; Tripathy, D.; Baly, D.; Baughman, S.A.; Twaddell, T.; Glaspy, J.A.; Slamon, D.J. Phase II study of receptor enhanced chemosensitivity using recombinant humanized antip185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2 overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 1998, 16, 2659-2671.
93. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Eng. J. Med., 2001, 344, 783-792.
94. Bang, Y.J.; Van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T.; Aprile, G.; Kulikov, E.; Hill, J.; Lehle, M.; Ruschoff, J.; Kang, Y.-K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): A phase III, open-label, randomised controlled trial. Lancet, 2010, 376, 687-697.
95. Arnould, L.; Gelly, M.; Penault-Llorca, F.; Benoit, L.; Bonnetain, F.; Migeon, C.; Cabaret, V.; Fermeaux, V.; Bertheau, P.; Garnier, J.; Jeannin, J.-F.; Coudert, B. Trastuzumab-based treatment of HER2-positive breast cancer. An antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer, 2006, 94, 259-267.
96. Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Bisagni, G.; Neri, T.M.; Ardizzoni, A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer. J. Clin. Oncol., 2008, 26, 1789-1796.
97. Perihar, R.; Dierksheide, J.; Hu, Y.; Carson, W.E. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J. Clin. Invest., 2002, 110, 983-992.
98. Harjunpaa, A.; Junnikkala, S.; Meri, S. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol., 2000, 51, 634-641.
99. Golay, J.; Zaffaroni, L.; Vaccari, T.; Lazzari, M.; Borlerim G.M.; Bernasconi, S.; Tedesco, F.; Rambaldi, A.; Introna, M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 2000, 95, 3900-3908.
100. Kim, S.Y.; Kim, H.P.; Kim, Y.J.; Oh do, Y.; Im, S.A.; Lee, D.; Jong, H.S.; Kim, T.Y.; Bang, Y.J. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int. J. Oncol., 2008, 32, 89-95.